



01-04-06

1fu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Commissioner of Patents
Alexander, Va. 22313-1450

January 2, 2006

Applicant: Reuben E. DeLoach

Number: 10 / 813384

RPA Filed: March 30, 2004 (Express mail)

RPA Title: "Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation"

Amendment A

In response to the Office Action mailed Oct 5, 2005, please amend the application as follows:

Information Disclosure Statement: Please replace the Information Disclosure Statement dated June 28, 2004, with the new Information Disclosure Statement and attachments provide herewith.

Claims: Please cancel all claims of record and substitute new claims 21 to 25 as follows:

21. A mono amine oxidase inhibitor hydrazide drug shuts down ongoing protein biosynthesis in cells which provides the method used to inhibit proteins including oxidase for antidepressant uses until the cell succumbs to apoptosis and is replaced, wherein improvements that provide a different purpose comprises the same method to shutdown ongoing protein biosynthesis in cells to inhibit metastatic or disease related proteins that likewise follows with apoptosis and cell replacements that are free of disease or DNA damage.

22. A method for targeting and eradicating diseased cells that are producing metastatic or disease related protein products for a patient in need thereof comprising the administering of a